Company Filing History:
Years Active: 2025
Title: Innovations of Elizabeth Ann Moroz in Cancer Treatment
Introduction
Elizabeth Ann Moroz is a notable inventor based in Collegeville, PA (US). She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target DNA methyltransferase 1 (DNMT1). Her work is crucial in the fight against various diseases, including cancer.
Latest Patents
Moroz holds a patent for "Substituted pyridines as DNMT1 inhibitors." This invention relates to substituted pyridine derivatives that inhibit the activity of DNMT1. The patent also encompasses pharmaceutical compositions that include these compounds and outlines methods for using them in treating cancer, pre-cancerous syndromes, beta haemoglobinopathy disorders, and other diseases linked to inappropriate DNMT1 activity. She has 1 patent to her name.
Career Highlights
Elizabeth Ann Moroz is associated with GlaxoSmithKline Intellectual Property Development Limited, where she continues to innovate in the pharmaceutical sector. Her research focuses on developing effective treatments that can significantly improve patient outcomes.
Collaborations
Some of her notable coworkers include Andrew B Benowitz and David T Fosbenner, who have collaborated with her on various projects within the company.
Conclusion
Elizabeth Ann Moroz's contributions to the field of pharmaceuticals, particularly through her patent on DNMT1 inhibitors, highlight her role as an influential inventor. Her work continues to pave the way for advancements in cancer treatment and other related diseases.